, Selon l'indication

, L'indication des AOD est conforme dans 100 % des cas, sous réserve de la

, Selon la posologie en fonction de l'indication

L. , AOD selon l'indication est non conforme dans 3,3 % des cas : elle est davantage non conforme de façon significative chez les patients sous dabigatran (81,8 %), que chez les patients sous rivaroxaban (0 %) et apixaban, p.9

, Parmi les posologies inadaptées, on note 2 patients sous dabigatran 2016/03, p.0, 2016.

, Les nouvelles recommandations de la Société Européenne de Cardiologie sur la fibrillation atriale

R. Cardiologiques, , 2017.

D. Sur,

O. Hanon, P. Assayag, J. Belmin, J. P. Collet, J. P. Emeriau et al., Expert consensus of the French Society of Geriatrics and Gerontology and the French Society of Cardiology on the management of atrial fibrillation in elderly people, Arch Cardiovasc Dis. mai, vol.106, issue.5, pp.303-326, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00879721

P. A. Wolf, R. D. Abbott, and W. B. Kannel, Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke. août, vol.22, issue.8, pp.983-991, 1991.

, Actualisation du rapport sur les anticoagulants en France : Etat des lieux en 2014 et recommandations de surveillance -Point d'information -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

T. Vogel, P. Lang, G. Kaltenbach, and P. Karcher, L'utilisation des anticoagulants oraux directs chez les patients âgés : les limites de la médecine fondée sur les preuves ? Rev Médecine Interne, vol.36, pp.840-842, 2015.

, Surveillance en vie réelle des anticoagulants oraux -Communiqué -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

S. Agarwal, R. Hachamovitch, and V. Menon, Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a metaanalysis, Arch Intern Med. 23 avr, vol.172, issue.8, pp.631-633, 2012.

O. Hanon, Les nouveaux anticoagulants oraux et la fibrillation atriale du sujet âgé, Gériatrie Psychol Neuropsychiatr Vieil. 1 déc, vol.11, issue.1, pp.34-40, 2013.

Y. Wang and B. Bajorek, New oral anticoagulants in practice: pharmacological and practical considerations, Am J Cardiovasc Drugs Drugs Devices Interv. juin, vol.14, issue.3, pp.175-89, 2014.

S. G. Garland, C. E. Deremer, S. M. Smith, and J. G. Gums, Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients, Ann Pharmacother. juin, vol.52, issue.6, pp.554-61, 2018.

B. I. Eriksson, O. E. Dahl, N. Rosencher, A. A. Kurth, C. N. Van-dijk et al., Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, Lancet Lond Engl. 15 sept, vol.370, issue.9591, pp.949-56, 2007.

B. I. Eriksson, L. C. Borris, R. J. Friedman, S. Haas, M. V. Huisman et al., Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, N Engl J Med. 26 juin, vol.358, issue.26, pp.2765-75, 2008.

M. R. Lassen, A. Gallus, G. E. Raskob, G. Pineo, D. Chen et al., Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, N Engl J Med. 23 déc, vol.363, issue.26, pp.2487-98, 2010.

B. I. Eriksson, O. E. Dahl, N. Rosencher, A. A. Kurth, C. N. Van-dijk et al., Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, J Thromb Haemost JTH, vol.5, issue.11, pp.2178-85, 2007.

M. R. Lassen, W. Ageno, L. C. Borris, J. R. Lieberman, N. Rosencher et al., Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, N Engl J Med. 26 juin, vol.358, issue.26, pp.2776-86, 2008.

M. R. Lassen, G. E. Raskob, A. Gallus, G. Pineo, D. Chen et al., Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. The Lancet. 6 mars, vol.375, pp.807-822, 2010.

, Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients | NEJM

S. Z. Goldhaber, A. Leizorovicz, A. K. Kakkar, S. K. Haas, G. Merli et al., Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients, N Engl J Med. 8 déc, vol.365, issue.23, pp.2167-77, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00721937

S. J. Connolly, M. D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med. 17 sept, vol.361, issue.12, pp.1139-51, 2009.

M. R. Patel, K. W. Mahaffey, J. Garg, G. Pan, D. E. Singer et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med. 8 sept, vol.365, issue.10, pp.883-91, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01038111

C. B. Granger, J. H. Alexander, J. Mcmurray, R. D. Lopes, E. M. Hylek et al., Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med. 15 sept, vol.365, issue.11, pp.981-92, 2011.

R. P. Giugliano, C. T. Ruff, E. Braunwald, S. A. Murphy, S. D. Wiviott et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N Engl J Med, vol.369, issue.22, pp.2093-104, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00934699

J. W. Eikelboom, S. J. Connolly, M. Brueckmann, C. B. Granger, A. P. Kappetein et al., Dabigatran versus warfarin in patients with mechanical heart valves, N Engl J Med. 26 sept, vol.369, issue.13, pp.1206-1220, 2013.
DOI : 10.1056/nejmoa1300615

S. Schulman, C. Kearon, A. K. Kakkar, P. Mismetti, S. Schellong et al., Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism, N Engl J Med. 10 déc, vol.361, issue.24, pp.2342-52, 2009.
URL : https://hal.archives-ouvertes.fr/ujm-00439704

S. Schulman, A. K. Kakkar, S. Z. Goldhaber, S. Schellong, H. Eriksson et al., Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation. 18 févr, vol.129, issue.7, pp.764-72, 2014.
DOI : 10.1161/circulationaha.113.004450

URL : https://hal.archives-ouvertes.fr/hal-01030866

M. H. Prins, A. W. Lensing, R. Bauersachs, B. Van-bellen, H. Bounameaux et al., Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thromb J. 20 sept, vol.11, p.21, 2013.

, Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism | NEJM

G. Agnelli, H. R. Buller, A. Cohen, M. Curto, A. S. Gallus et al., Oral Apixaban for the Treatment of Acute Venous Thromboembolism, N Engl J Med. 29 août, vol.369, issue.9, pp.799-808, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00932477

, Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism, N Engl J Med, vol.369, issue.15, pp.1406-1421, 2013.

E. Romualdi, M. P. Donadini, and W. Ageno, Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study), Expert Rev Cardiovasc Ther. juill, vol.9, issue.7, pp.841-845, 2011.
DOI : 10.1586/erc.11.62

G. Agnelli, H. R. Buller, A. Cohen, M. Curto, A. S. Gallus et al., Apixaban for extended treatment of venous thromboembolism, N Engl J Med, vol.21, issue.8, pp.699-708, 2013.
DOI : 10.1097/sa.0b013e3182a495a4

URL : https://hal.archives-ouvertes.fr/hal-00771313

J. Oldgren, A. Budaj, C. B. Granger, Y. Khder, J. Roberts et al., Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial, Eur Heart J, vol.32, issue.22, pp.2781-2790, 2011.

G. N. Shivu and N. Ossei-gerning, Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vasc Health Risk Manag, 12 mai, vol.10, pp.291-302, 2014.

J. H. Alexander, R. D. Lopes, S. James, R. Kilaru, Y. He et al., Apixaban with antiplatelet therapy after acute coronary syndrome, N Engl J Med. 25 août, vol.365, issue.8, pp.699-708, 2011.
DOI : 10.1056/nejmoa1105819

URL : http://espace.library.uq.edu.au/view/UQ:382418/UQ382418_OA.pdf

J. W. Eikelboom, S. J. Connolly, J. Bosch, G. R. Dagenais, R. G. Hart et al., Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease, N Engl J Med. 05, vol.377, issue.14, pp.1319-1349, 2017.
DOI : 10.1056/nejmoa1709118

URL : https://hal.archives-ouvertes.fr/hal-01892329

F. Zannad, S. D. Anker, W. M. Byra, J. Cleland, M. Fu et al., Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease, N Engl J Med

A. J. Camm, P. Amarenco, S. Haas, S. Hess, P. Kirchhof et al., XANTUS: a realworld, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation, Eur Heart J. 7 avr, vol.37, issue.14, pp.1145-53, 2016.

, Étude 'en vie réelle' du bénéfice/risque à court terme des nouveaux anticoagulants oraux (dabigatran, rivaroxaban) chez les patients débutant un traitement et non précédemment traités par des AVK, Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAMTS), 2014.

M. Gilles-schiele-françois, Post-ESC 2018 : dernières actualités dans le domaine de l'anticoagulation orale | e-Direct TV | La web tv des médecins spécialistes, 2018.

J. Steffel, P. Verhamme, T. S. Potpara, P. Albaladejo, M. Antz et al., European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur Heart J. 21 avr, vol.39, issue.16, pp.1330-93, 2018.

A. Rapport, Comité Technique du Réseau français des centres régionaux de pharmacovigilance, 2017.

, Haute Autorité de Santé -Les anticoagulants oraux

D. Sur,

P. Sié, Bilan d'hémostase chez les patients traités par un anticoagulant oral direct (AOD). Datarevues07554982v44i7-8S0755498215003103, 2015.

D. Sur,

P. Albaladejo, F. Bonhomme, N. Blais, J. Collet, D. Faraoni et al., Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: Updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP), Anaesth Crit Care Pain Med. févr, vol.36, issue.1, pp.73-79, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01809407

P. A. Reilly, T. Lehr, S. Haertter, S. J. Connolly, S. Yusuf et al., The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), J Am Coll Cardiol. 4 févr, vol.63, issue.4, pp.321-329, 2014.

E. Chaussade, O. Hanon, C. Boully, F. Labourée, L. Caillard et al., RealLife Peak and Trough Dabigatran Plasma Measurements over Time in Hospitalized Geriatric Patients with Atrial Fibrillation, J Nutr Health Aging, vol.22, issue.1, pp.165-73, 2018.

P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thorac Surg Off J Eur Assoc Cardio-Thorac Surg, vol.50, pp.1-88, 2016.

B. F. Gage, A. D. Waterman, W. Shannon, M. Boechler, M. W. Rich et al., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation, JAMA. 13 juin, vol.285, issue.22, pp.2864-70, 2001.

R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De-vos, H. Crijns et al., A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey, Chest, vol.138, issue.5, pp.1093-100, 2010.

E. C. O'brien, D. N. Simon, L. E. Thomas, E. M. Hylek, B. J. Gersh et al., The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation, Eur Heart J. 7 déc, vol.36, issue.46, pp.3258-64, 2015.

B. F. Gage, Y. Yan, P. E. Milligan, A. D. Waterman, R. Culverhouse et al., Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF), Am Heart J. mars, vol.151, issue.3, pp.713-722, 2006.

, ESC Guidelines on the diagnosis and management of acute pulmonary embolism, European Heart Journal | Oxford Academic, 2014.

P. S. Wells, D. R. Anderson, M. Rodger, J. S. Ginsberg, C. Kearon et al., Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer, Thromb Haemost. mars, vol.83, issue.3, pp.416-436, 2000.

J. Wicki, T. V. Perneger, A. F. Junod, H. Bounameaux, and A. Perrier, Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score, Arch Intern Med. 8 janv, vol.161, issue.1, pp.92-99, 2001.

, Prévention de la maladie thromboembolique veineuse postopératoire. Actualisation 2011. Texte court -La SFAR

. Société-française-d'anesthésie and . De-réanimation, Population par âge ? Tableaux de l'Économie Française | Insee, 2015.

R. E. Pel-littel, M. J. Schuurmans, M. H. Emmelot-vonk, and H. Verhaar, Frailty: defining and measuring of a concept, J Nutr Health Aging. avr, vol.13, issue.4, pp.390-394, 2009.

K. Mangerel, A. -. Branger, S. Rhalimi, and M. , Specificities of the elderly and its impact on drug therapy, J Pharm Clin. 1 sept, vol.30, issue.3, pp.167-73, 2011.

M. Daroux, C. Gaxatte, F. Puisieux, B. Corman, and É. Boulanger, Vieillissement rénal : facteurs de risque et néphroprotection

D. Sur,

K. Turnheim, When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly, Exp Gerontol. août, vol.38, issue.8, pp.843-53, 2003.

. Hcaam and . Personnes_agees_etat_de_sante_et_dependance_quelques_elements_statistiques, , 2015.

J. Dartigues, C. Helmer, L. Letenneur, K. Péres, H. Amieva et al.,

, Geriatr Psychol Neuropsychiatr Vieil. sept, vol.10, issue.3, pp.325-356, 2012.

. Paitraud-d, Iatrogénie médicamenteuse chez les personnes âgées : enquête, campagne de sensibilisation et actions annoncées du Leem

. Vidal, , 2015.

M. H. Beers, J. G. Ouslander, I. Rollingher, D. B. Reuben, J. Brooks et al., Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine, Arch Intern Med. sept, vol.151, issue.9, pp.1825-1857, 1991.
DOI : 10.1001/archinte.1991.00400090107019

M. Laroche, F. Bouthier, M. L. Charmes, and J. , Médicaments potentiellement inappropriés aux personnes âgées : intérêt d'une liste adaptée à la pratique médicale française, Rev Médecine Interne. 1 juill, vol.30, issue.7, pp.592-601, 2009.
DOI : 10.1016/j.revmed.2008.08.010

P. O. Lang, M. Dramé, B. Guignard, R. Mahmoudi, I. Payot et al., Les critères STOPP/START.v2 : adaptation en langue française, NPG Neurol -PsychiatrGériatrie. 1 déc, vol.15, issue.90, pp.323-359, 2015.
DOI : 10.1016/j.actpha.2017.11.006

, Haute Autorité de Santé -Comment améliorer la qualité et la sécurité des prescriptions de médicaments chez la personne âgée ?

D. Sur,

H. Robert-ebadi, L. Gal, G. Righini, and M. , Use of anticoagulants in elderly patients: practical recommendations, Clin Interv Aging, vol.4, pp.165-77, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00683243

M. C. Fang, A. S. Go, Y. Chang, L. H. Borowsky, N. K. Pomernacki et al., A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study, J Am Coll Cardiol. 19 juill, vol.58, issue.4, pp.395-401, 2011.

C. Soave, E. Chidlovskii, A. Lebelhomme, Y. Gaboreau, G. Pernod et al., Comparison of the HAS-BLED and ATRIA scores for the risk of bleeding in patients aged 75 and over receiving vitamin K antagonist (VKA) therapy
URL : https://hal.archives-ouvertes.fr/hal-02123229

, Geriatr Psychol Neuropsychiatr Vieil. sept, vol.13, issue.3, pp.279-88, 2015.

E. M. Hylek, A. S. Go, Y. Chang, N. G. Jensvold, L. E. Henault et al., Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation, N Engl J Med. 11 sept, vol.349, issue.11, pp.1019-1045, 2003.

M. Torn, W. Bollen, F. Van-der-meer, E. E. Van-der-wall, and F. R. Rosendaal, Risks of oral anticoagulant therapy with increasing age, Arch Intern Med. 11 juill, vol.165, issue.13, pp.1527-1559, 2005.

J. Doucet, E. Gréboval-furstenfeld, A. Tavildari, M. 'bello, L. Delaunay et al., Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly, Fundam Clin Pharmacol, vol.22, issue.5, pp.569-74, 2008.

A. Perrin and Y. Rolland, Traitement anticoagulant oral chez les patients âgés, Ann Gérontologie. 1 sept, vol.3, issue.3, pp.189-96, 2010.

J. Mant, F. R. Hobbs, K. Fletcher, A. Roalfe, D. Fitzmaurice et al., Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. The Lancet. 11 août, vol.370, pp.493-503, 2007.

A. S. Go, E. M. Hylek, K. A. Phillips, Y. Chang, L. E. Henault et al., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study, JAMA. 9 mai, vol.285, issue.18, pp.2370-2375, 2001.

C. Moreau, E. Pautas, I. Gouin-thibault, J. Golmard, I. Mahé et al., Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes, J Thromb Haemost JTH. avr, vol.9, issue.4, pp.711-719, 2011.

C. T. Ruff, R. P. Giugliano, E. Braunwald, E. B. Hoffman, N. Deenadayalu et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet Lond Engl. 15 mars, vol.383, issue.9921, pp.955-62, 2014.
URL : https://hal.archives-ouvertes.fr/hal-00935589

T. Vogel, E. Andrès, B. Geny, G. Kaltenbach, and P. Lang, Les anticoagulants oraux directs en 2015 chez le patient âgé : focus chez le sujet fragile, Cah Année Gérontologique. 1 sept, vol.7, issue.3, pp.122-159, 2015.

O. Hanon, J. Vidal, L. Heuzey, J. Kirchhof, P. et al., Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF, Int J Cardiol. 1 avr, vol.232, pp.98-104, 2017.

T. Trebesses, Évènements hémorragiques dans une population gériatrique nouvellement traitée par anticoagulation orale pour fibrillation atriale, vol.74, 2018.

T. Lafon, C. Vallejo, M. Hadj, M. Laroche, and H. Geniaux, Mésusage et iatrogénie des anticoagulants oraux directs (AOD) : étude observationnelle dans le service des urgences du CHU de Limoges, Thérapie. 19 mai, vol.73, issue.3, pp.209-224, 2018.

F. Moustafa, J. Chedjieu, J. Saint-denis, A. Barres, N. Dublanchet et al., Étude en vie réelle concernant 357 patients sous anticoagulant oral direct se présentant consécutivement dans un service d'urgence, JMV-J Médecine Vasc. 1 mars, vol.42, issue.2, p.101, 2017.

L. Rédaction and . Jasfgg, Anticoagulants oraux directs (AOD) : l'épreuve de la vraie vie, 2016.

D. Sur,

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-83, 1987.

B. Lesourd, F. Ziegler, and C. Aussel, La nutrition des personnes âgées : place et pièges du bilan biologique, Ann Biol Clin (Paris). 24 juill, vol.59, issue.4, pp.445-52, 2001.

, Personnes âgées dépendantes ? Tableaux de l'Économie Française | Insee

M. Cecile, V. Seux, V. Pauly, S. Tassy, O. Reynaud-levy et al., Accidents iatrogènes médicamenteux chez le sujet âgé hospitalisé en court séjour gériatrique : étude de prévalence et des facteurs de risques, Rev Médecine Interne. mai, vol.30, issue.5, pp.393-400, 2009.

C. V. Pollack, P. A. Reilly, J. Eikelboom, S. Glund, P. Verhamme et al., Idarucizumab for Dabigatran Reversal, N Engl J Med. 6 août, vol.373, issue.6, pp.511-531, 2015.

A. Lobo, L. J. Launer, L. Fratiglioni, K. Andersen, D. Carlo et al., Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group, Neurology, vol.54, issue.11, pp.4-9, 2000.

, Haute Autorité de Santé -Stratégie de prise en charge en cas de dénutrition protéino-énergétique chez la personne âgée

M. Man-son-hing, N. G. Lau, A. Laupacis, and A. , Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls, Arch Intern Med. 12 avr, vol.159, issue.7, pp.677-85, 1999.

C. Carbonnel, V. Seux, V. Pauly, C. Oddoze, C. Roubicek et al., Quelle méthode d'évaluation de la fonction rénale utiliser chez le sujet âgé hospitalisé en unité de court séjour gériatrique ? Comparaison de quatre méthodes, 2008.

D. Sur,

B. A. Steinberg, E. D. Peterson, S. Kim, L. Thomas, B. J. Gersh et al., Use and outcomes associated with bridging during anticoagulation interruptions in patients with 96 atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), Circulation. 3 févr, vol.131, issue.5, pp.488-94, 2015.

T. I. Shireman, P. A. Howard, T. F. Kresowik, and E. F. Ellerbeck, Combined anticoagulantantiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke, vol.35, pp.2362-2369, 2004.

M. Ledroit, M. M. Wabo, A. Berroneau, C. Mouton, Y. Pucheu et al., Optimisation du bon usage des anticoagulants oraux directs (ACOD) via une démarche d'évaluation des pratiques professionnelles, Pharm Hosp Clin. b>Date</b>, vol.25, issue.1, pp.51-58, 2016.

, Quelle est la situation actuelle de l'utilisation des NACO? -ANSM : Agence nationale de sécurité du médicament et des produits de santé

D. Sur,

, Direct Oral Anticoagulants appropriateness' prescriptions in a French University Hospital Center in 2016, Fundam Clin Pharmacol, vol.31, issue.S1, pp.51-79

, Projet de recherche SAFIR -aprobasso

D. Sur,

, Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study | The BMJ

D. Sur,

P. Sardar, S. Chatterjee, S. Chaudhari, and G. Lip, New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials, J Am Geriatr Soc. mai, vol.62, issue.5, pp.857-64, 2014.

O. Hanon, E. Chaussade, P. Gueranger, E. Gruson, S. Bonan et al., Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study, PloS One, vol.11, issue.12, 2016.